{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:32:33Z","timestamp":1789612353543,"version":"build-2803163510"},"reference-count":110,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019465","name":"Arab-German Young Academy of Sciences and Humanities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","award":["01DL20003"],"award-info":[{"award-number":["01DL20003"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbcan.2026.189685","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:55:19Z","timestamp":1786722919000},"page":"189685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nano meets CAR-T: A new era in cancer immunotherapy"],"prefix":"10.1016","volume":"1881","author":[{"given":"Alaa","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bbcan.2026.189685_bb0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"6382","key":"10.1016\/j.bbcan.2026.189685_bb0010","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189685_bb0015","first-page":"189","article-title":"CAR-T in cancer therapeutics and updates","volume":"4","author":"Zhu","year":"2024","journal-title":"J Natl Cancer Cent."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189685_bb0020","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189685_bb0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189685_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/cai2.70053","article-title":"Combining small-molecular compounds with CAR T-cell therapy: novel strategies for enhanced cancer immunotherapy","volume":"5","author":"Yi","year":"2026","journal-title":"Cancer Innov."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-026-01793-8","article-title":"CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting","volume":"19","author":"Geng","year":"2026","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-71354-7","article-title":"Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination","volume":"17","author":"Warmuth","year":"2026","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189685_bb0045","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189685_bb0050","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189685_bb0065","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.apsb.2020.10.020","article-title":"CAR-T cells: early successes in blood cancer and challenges in solid tumors","volume":"11","author":"Dana","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189685_bb0075","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189685_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101028","article-title":"Current state of CAR-T cell therapies for solid tumors","author":"Rosa","year":"2026","journal-title":"Med"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189685_bb0085","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/2643-3230.BCD-23-0272","article-title":"The fate(s) of CAR T-cell therapy: navigating the risks of CAR+ T-cell malignancy","volume":"5","author":"Abou-El-Enein","year":"2024","journal-title":"Blood Cancer Discov."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189685_bb0090","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.3390\/cancers14235983","article-title":"Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189685_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1519671","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2025","journal-title":"Front. Immunol."},{"issue":"82","key":"10.1016\/j.bbcan.2026.189685_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq3016","article-title":"Metabolic challenges and interventions in CAR T cell therapy","volume":"8","author":"Peng","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbcan.2026.189685_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.925985","article-title":"CAR T-cell-based gene therapy for cancers: new perspectives, challenges, and clinical developments","volume":"13","author":"Jogalekar","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189685_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/mmr.2024.13171","article-title":"CAR-T cell therapy: a breakthrough in traditional cancer treatment strategies (Review)","volume":"29","author":"Sun","year":"2024","journal-title":"Mol. Med. Rep."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189685_bb0115","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/d41573-023-00140-7","article-title":"The next-generation CAR-T therapy landscape","volume":"22","author":"Verma","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189685_bb0120","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41565-025-02008-w","article-title":"Nanotechnology for CAR T cells and tumour-infiltrating lymphocyte therapies","volume":"20","author":"Lafuente-G\u00f3mez","year":"2025","journal-title":"Nat. Nanotechnol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189685_bb0125","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.3390\/ijms25105361","article-title":"Current advancements in anti-cancer chimeric antigen receptor T cell immunotherapy and how nanotechnology may change the game","volume":"25","author":"Ku","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189685_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2024.1479993","article-title":"Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials","volume":"6","author":"Kumarasamy","year":"2024","journal-title":"Front Nanotechnol."},{"key":"10.1016\/j.bbcan.2026.189685_bb0135","first-page":"124","article-title":"CAR-T and nanotechnology: a comparative perspective on autoimmune disease and cancer","volume":"7","author":"Pavithra","year":"2025","journal-title":"Adv Biomark Sci Technol."},{"key":"10.1016\/j.bbcan.2026.189685_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.600659","article-title":"Nanoparticles for enhanced adoptive T cell therapies and future perspectives for CNS tumors","volume":"12","author":"Balakrishnan","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189685_bb0145","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.tcb.2024.11.010","article-title":"Harnessing nanoengineered CAR-T cell strategies to advance solid tumor immunotherapy","volume":"35","author":"Wang","year":"2025","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bbcan.2026.189685_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.849759","article-title":"Advances in nanotechnology development to overcome current roadblocks in CAR-T therapy for solid tumors","volume":"13","author":"Mi","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0155","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12951-024-02630-1","article-title":"Steering the course of CAR T cell therapy with lipid nanoparticles","volume":"22","author":"Khawar","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.bbcan.2026.189685_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2022.100035","article-title":"Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; a comprehensive review","volume":"4","author":"Ahmad","year":"2022","journal-title":"Adv. Cancer Biol. Metastasis"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189685_bb0170","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189685_bb0175","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189685_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.797440","article-title":"Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions","volume":"10","author":"Alnefaie","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.bbcan.2026.189685_bb0185","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2147\/DDDT.S413348","article-title":"CAR T cell therapy: remedies of current challenges in design, injection, infiltration and working","volume":"17","author":"Zhu","year":"2023","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bbcan.2026.189685_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions related to CAR-T cell therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189685_bb0195","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated MRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.bbcan.2026.189685_bb0200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189685_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.107747","article-title":"Application of nanotechnology in CAR-T-cell immunotherapy","volume":"34","author":"Zeng","year":"2023","journal-title":"Chin. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189685_bb0210","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s12032-025-02923-x","article-title":"CAR T-cell therapy in hematologic and solid malignancies: mechanisms, clinical applications, and future directions","volume":"42","author":"Kuttiappan","year":"2025","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01744-9","article-title":"Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?","volume":"18","author":"Vo","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189685_bb0220","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0225","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189685_bb0230","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/cells14171398","article-title":"Cancer-associated fibroblasts in solid tumors and sarcomas: heterogeneity, function, and therapeutic implications","volume":"14","author":"Badran","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0235","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-024-01848-7","article-title":"Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0240","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","article-title":"Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy","volume":"24","author":"Lu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189685_bb0245","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0250","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189685_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1749965","article-title":"Targeting MDSCs in cancer: emerging immunotherapeutic and metabolic strategies","volume":"17","author":"Dash","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189685_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1034257","article-title":"Mechanisms of CAR T cell exhaustion and current counteraction strategies","volume":"10","author":"Zhu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189685_bb0265","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after Chimeric Antigen Receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"21","key":"10.1016\/j.bbcan.2026.189685_bb0270","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.3390\/jcm13216537","article-title":"Next-generation immunotherapy: advancing clinical applications in cancer treatment","volume":"13","author":"Garg","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbcan.2026.189685_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113786","article-title":"Targeting tumor extracellular matrix with nanoparticles to circumvent therapeutic resistance","volume":"383","author":"Ding","year":"2025","journal-title":"J. Control. Release"},{"issue":"Pt 3","key":"10.1016\/j.bbcan.2026.189685_bb0280","article-title":"Thermosensitive hyaluronic acid-manganese-capsaicin complex nanogel improving NKG2D\/CAR-T melanoma treatment through adjusting tumor microenvironment","volume":"281","author":"Wang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189685_bb0285","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.7150\/ijbs.122417","article-title":"Dual targeting of FAP-directed nanoparticles and FR\u03b1-specific CAR-T cells induces additive antitumor effects in triple-negative breast cancer","volume":"22","author":"Thongkleang","year":"2026","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189685_bb0290","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1021\/acs.molpharmaceut.5c01508","article-title":"Ex vivo zinc nanoparticle conditioning primes T cells for potent antitumor activity in ovarian cancer patient-derived xenografts","volume":"23","author":"Gong","year":"2026","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0295","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","article-title":"Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy","volume":"17","author":"Lu","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0300","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12943-025-02476-7","article-title":"Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives","volume":"24","author":"Shang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"14","key":"10.1016\/j.bbcan.2026.189685_bb0305","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn8264","article-title":"Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors","volume":"8","author":"Grosskopf","year":"2022","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189685_bb0310","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s13770-022-00515-8","article-title":"Nanoparticle-based chimeric antigen receptor therapy for cancer immunotherapy","volume":"20","author":"Shin","year":"2023","journal-title":"Tissue Eng. Regener. Med."},{"key":"10.1016\/j.bbcan.2026.189685_bb0315","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/IJN.S229858","article-title":"Self-assembled nanoparticles prepared from low-molecular-weight PEI and low-generation PAMAM for EGFRvIII-chimeric antigen receptor gene loading and T-cell transient modification","volume":"15","author":"Yu","year":"2020","journal-title":"Int. J. Nanomedicine"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189685_bb0320","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.2005","article-title":"Nanotechnology-assisted CAR-T-cell therapy for tumor treatment","volume":"16","author":"Wang","year":"2024","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189685_bb0325","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10716","article-title":"Advances in bioengineered CAR T\/NK cell therapy for glioblastoma: overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T\/NK cell therapy","volume":"10","author":"Dana","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189685_bb0330","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-025-04185-5","article-title":"Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology","author":"Dong","year":"2026","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bbcan.2026.189685_bb0335","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","article-title":"Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy","volume":"372","author":"Soroudi","year":"2024","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189685_bb0340","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/pharmaceutics16091228","article-title":"Nanotechnology in advancing chimeric antigen receptor T cell therapy for cancer treatment","volume":"16","author":"Kang","year":"2024","journal-title":"Pharmaceutics"},{"issue":"21","key":"10.1016\/j.bbcan.2026.189685_bb0345","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1097\/CM9.0000000000003706","article-title":"Innovative strategies for improving CAR-T cell therapy: a nanomedicine perspective","volume":"138","author":"Wang","year":"2025","journal-title":"Chin. Med. J."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189685_bb0350","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202410975","article-title":"Enhancing chimeric antigen receptor T-cell generation via microfluidic mechanoporation and lipid nanoparticles","volume":"21","author":"Lim","year":"2025","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202501475","article-title":"Co-delivery of multiple RNAs via lipid nanoparticles enables precise gene editing of CAR-T cells","volume":"15","author":"Wang","year":"2026","journal-title":"Adv. Healthc. Mater."},{"issue":"6753","key":"10.1016\/j.bbcan.2026.189685_bb0360","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189685_bb0365","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1021\/acsami.5c21115","article-title":"Class II peptide-major histocompatibility complex lipid nanoparticles enable in vivo mRNA delivery to antigen-specific CD4+ T cells","volume":"18","author":"Choy","year":"2026","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bbcan.2026.189685_bb0370","article-title":"1202\u00a0in vivo engineering of CAR T cells using a novel targeted LNP-mRNA technology","volume":"11","author":"Adams","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189685_bb0375","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","article-title":"Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo","volume":"350","author":"Zhou","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2026.189685_bb0380","article-title":"Distinct effector functions and synergy of CAR mRNA-engineered T cells and macrophages in the clearance of CD19+ leukemia cells","author":"Liao","year":"2026","journal-title":"J. Adv. Res."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189685_bb0385","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189685_bb0390","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/thno.40291","article-title":"Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment","volume":"10","author":"Ma","year":"2020","journal-title":"Theranostics"},{"issue":"23","key":"10.1016\/j.bbcan.2026.189685_bb0395","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201970166","article-title":"Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells","volume":"31","author":"Chen","year":"2019","journal-title":"Adv. Mater."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189685_bb0400","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1039\/D4BM01305K","article-title":"Bioorthogonal oncolytic-virus nanovesicles combined bio-immunotherapy with CAR-T cells for solid tumors","volume":"13","author":"Huang","year":"2025","journal-title":"Biomater. Sci."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189685_bb0405","doi-asserted-by":"crossref","first-page":"8212","DOI":"10.1021\/acsnano.4c17899","article-title":"Tumor microenvironment-responsive nano-immunomodulators for enhancing chimeric antigen receptor-T cell therapy in lung cancer","volume":"19","author":"Chen","year":"2025","journal-title":"ACS Nano"},{"issue":"26","key":"10.1016\/j.bbcan.2026.189685_bb0410","article-title":"Antigen presenting cell mimetic lipid nanoparticles for rapid MRNA CAR T cell cancer immunotherapy","volume":"36","author":"Metzloff","year":"2024","journal-title":"Adv. Mater."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189685_bb0415","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nbt.4047","article-title":"Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells","volume":"36","author":"Cheung","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0420","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41467-024-55751-4","article-title":"Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189685_bb0425","first-page":"422","article-title":"Targeted chemotherapy via HER2-based Chimeric Antigen Receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles","volume":"34","author":"Yaman","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.bbcan.2026.189685_bb0430","first-page":"73","article-title":"Artifical intelligence in tumor drug resistance: mechanisms and treatment prospects","volume":"1","author":"Gu","year":"2025","journal-title":"Int Oncol"},{"key":"10.1016\/j.bbcan.2026.189685_bb0435","first-page":"1","article-title":"We need intelligent oncology everywhere","volume":"1","author":"Cavalli","year":"2025","journal-title":"Int Oncol"},{"key":"10.1016\/j.bbcan.2026.189685_bb0440","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/med4.75","article-title":"Automated machine learning with interpretation: a systematic review of methodologies and applications in healthcare","volume":"2","author":"Yuan","year":"2024","journal-title":"Med Adv"},{"key":"10.1016\/j.bbcan.2026.189685_bb0445","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/med4.62","article-title":"Applications of artificial intelligence and machine learning in clinical medicine: what lies ahead?","volume":"2","author":"Raj","year":"2024","journal-title":"Med Adv"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189685_bb0450","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41551-024-01216-4","article-title":"Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells","volume":"9","author":"Zhang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189685_bb0455","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189685_bb0460","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.fmre.2023.05.016","article-title":"A Tetramethylpyrazine releasing hydrogel can potentiate CAR-T cell therapy against triple negative breast cancer by reprogramming tumor vasculatures","volume":"5","author":"Liu","year":"2023","journal-title":"Fundam. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0465","article-title":"Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy","volume":"17","author":"Zheng","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0470","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","article-title":"Orthogonal design of experiments for optimization of lipid nanoparticles for MRNA engineering of CAR T cells","volume":"22","author":"Billingsley","year":"2022","journal-title":"Nano Lett."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189685_bb0475","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189685_bb0480","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjh.19988","article-title":"mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells","volume":"206","author":"Chen","year":"2025","journal-title":"Br. J. Haematol."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189685_bb0485","doi-asserted-by":"crossref","first-page":"15668","DOI":"10.1021\/acsnano.4c18153","article-title":"Chimeric antigen receptor-engineered cell membrane-coated nanoparticles promote dual-targeted MRNA-based cancer gene therapy","volume":"19","author":"Lei","year":"2025","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189685_bb0490","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.scib.2023.11.055","article-title":"In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles","volume":"69","author":"Zhao","year":"2024","journal-title":"Sci. Bull. (Beijing)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0495","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1038\/s41467-023-41631-w","article-title":"Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189685_bb0500","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-23-0677","article-title":"Knocking out CD70 rescues CD70-specific NanoCAR T cells from antigen-induced exhaustion","volume":"12","author":"De Munter","year":"2024","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189685_bb0505","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1158\/2326-6066.CIR-19-0734","article-title":"Improved antitumor efficacy of chimeric antigen receptor T cells that secrete single-domain antibody fragments","volume":"8","author":"Xie","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189685_bb0510","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0515","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12967-024-05159-x","article-title":"Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology","volume":"22","author":"Lin","year":"2024","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189685_bb0520","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/iub.2019","article-title":"T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy","volume":"71","author":"Hajari Taheri","year":"2019","journal-title":"IUBMB Life"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189685_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202407425","article-title":"Photo-metallo-immunotherapy: fabricating chromium-based nanocomposites to enhance CAR-T cell infiltration and cytotoxicity against solid tumors","volume":"37","author":"Zou","year":"2025","journal-title":"Adv. Mater."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189685_bb0530","doi-asserted-by":"crossref","first-page":"16770","DOI":"10.1021\/acsnano.3c03456","article-title":"Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy","volume":"17","author":"Zhu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbcan.2026.189685_bb0535","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.2147\/IJN.S508846","article-title":"Gas vesicle-assisted ultrasound imaging for effective anti-tumour CAR-T cell immunotherapy efficacy in mice model","volume":"20","author":"Huang","year":"2025","journal-title":"Int. J. Nanomedicine"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189685_bb0540","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202308254","article-title":"Tumor microenvironment modulating CaCO3-based colloidosomal microreactors can generally reinforce cancer immunotherapy","volume":"36","author":"Dong","year":"2024","journal-title":"Adv. Mater."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189685_bb0545","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202007494","article-title":"Nanoengineered CAR-T biohybrids for solid tumor immunotherapy with microenvironment photothermal-remodeling strategy","volume":"17","author":"Chen","year":"2021","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189685_bb0550","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70039","article-title":"Loading of CAR-T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism","volume":"6","author":"Pfister","year":"2025","journal-title":"MedComm"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189685_bb0555","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202414368","article-title":"In vivo monitoring and magnetically-enhanced delivery of CAR T-cells to solid tumor","volume":"35","author":"Chen","year":"2025","journal-title":"Adv. Funct. Mater."},{"issue":"40","key":"10.1016\/j.bbcan.2026.189685_bb0560","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1039\/C8TB01930D","article-title":"Two-photon fluorescent polydopamine nanodots for CAR-T cell function verification and tumor cell\/tissue detection","volume":"6","author":"Ma","year":"2018","journal-title":"J. Mater. Chem. B"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:23:05Z","timestamp":1789518185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":110,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0304419X26001575"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189685","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nano meets CAR-T: A new era in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189685","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189685"}}